Imaging for Metastatic Renal Cell Carcinoma.
CT
MRI
Metastatic disease
PET
Renal cell carcinoma
Journal
The Urologic clinics of North America
ISSN: 1558-318X
Titre abrégé: Urol Clin North Am
Pays: United States
ID NLM: 0423221
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
entrez:
1
7
2020
pubmed:
1
7
2020
medline:
4
7
2020
Statut:
ppublish
Résumé
Patients with renal cell carcinoma may develop metastases after radical nephrectomy, and therefore monitoring with imaging for recurrent or metastatic disease is critical. Imaging varies with specific suspected site of disease. Computed tomography/MRI of the abdomen and pelvis are mainstay modalities. Osseous and central nervous system imaging is reserved for symptomatic patients. Radiologic reporting is evolving to reflect effects of systemic therapy on lesion morphology. Nuclear medicine studies compliment routine imaging as newer agents are evaluated for more accurate tumor staging. Imaging research aims to fill gaps in treatment selection and monitoring of treatment response in metastatic renal cell carcinoma.
Identifiants
pubmed: 32600531
pii: S0094-0143(20)30020-3
doi: 10.1016/j.ucl.2020.04.005
pmc: PMC7327136
mid: NIHMS1586277
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
281-291Subventions
Organisme : NCI NIH HHS
ID : K07 CA197134
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure Dr S.K. Kang reports royalties from Wolters Kluwer for unrelated work. Dr E. Zan is involved in clinical trial support at AAA/Novartis and Perlmutter Cancer Center for unrelated work, and acting as a Co-PI in a study at the NIH for unrelated work. Dr S.V.L. Vig has no disclosures.
Références
Urology. 2007 Aug;70(2):385-90
pubmed: 17826525
Radiographics. 2013 Oct;33(6):1691-716
pubmed: 24108558
Urol Clin North Am. 2003 Nov;30(4):843-52
pubmed: 14680319
Curr Oncol. 2009 May;16 Suppl 1:S40-4
pubmed: 19478896
Am Soc Clin Oncol Educ Book. 2016;35:113-7
pubmed: 27249692
J Urol. 2004 May;171(5):1806-9
pubmed: 15076281
JAMA. 2006 Jun 7;295(21):2516-24
pubmed: 16757724
J Urol. 2017 Sep;198(3):520-529
pubmed: 28479239
J Urol. 2001 Dec;166(6):2126-8
pubmed: 11696720
AJR Am J Roentgenol. 2017 Dec;209(6):1278-1284
pubmed: 29064751
Ann Nucl Med. 2015 Dec;29(10):877-82
pubmed: 26286635
J Clin Oncol. 2013 Jan 10;31(2):187-94
pubmed: 23213092
AJR Am J Roentgenol. 2015 Mar;204(3):W282-8
pubmed: 25714313
Ther Adv Urol. 2015 Dec;7(6):365-77
pubmed: 26622321
Dis Markers. 2015;2015:648495
pubmed: 26609190
Urology. 2008 Jul;72(1):230.e5-6
pubmed: 18329075
World J Nucl Med. 2015 Jan-Apr;14(1):36-40
pubmed: 25709543
Urologe A. 1996 Mar;35(2):146-50
pubmed: 8650849
AJR Am J Roentgenol. 2012 Jun;198(6):1266-76
pubmed: 22623538
AJR Am J Roentgenol. 2008 Oct;191(4):1220-32
pubmed: 18806169
Radiol Clin North Am. 2017 Nov;55(6):1235-1250
pubmed: 28991563
Lancet Oncol. 2007 Apr;8(4):304-10
pubmed: 17395103
Eur J Cancer. 2016 Jul;62:132-7
pubmed: 27189322
J Am Coll Radiol. 2016 May;13(5):518-25
pubmed: 27016804
Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1461-2
pubmed: 24756358
Cochrane Database Syst Rev. 2005 Jan 25;(1):CD001425
pubmed: 15674877
AJR Am J Roentgenol. 2007 Aug;189(2):360-70
pubmed: 17646462
AJR Am J Roentgenol. 2014 Aug;203(2):261-2
pubmed: 25055257